Clinical trial · Observational
Clinical Study of Imaging Genomics Based on Machine Learning for BCIG
Clinical Study of Imaging Genomics Based on Machine Learning for Breast Cancer Molecular Typing and Risk Prediction (BCIG)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. Identify the imaging features of breast cancer with different molecular types 2. Reveal the association between hormone receptor positive/HER2 negative breast cancer and imaging histology, Oncotype Dx recurrence score 3. Combine genomics and imaging to establish a predictive model for the sensitivity of HER2-positive breast cancer targeted therapy 4. Establish an imaging genomics prediction model for triple-negative breast cancer molecular subtypes, and clarify the imaging genomics characteristics of the therapeutic targets of each subtype
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Image, Body | — | UNRESOLVED | — |
| Molecular Typing | — | UNRESOLVED | — |
| Pathology | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Multidisciplinary cooperative comprehensive treatment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Luminal
- description
- Luminal A：ER+ and/or PR+,HER2- Luminal B：ER+ and/or PR+,HER2+ \* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2
- interventionNames
- Procedure: Multidisciplinary cooperative comprehensive treatment
- label
- HER2 overexpression
- description
- ER- PR-,HER2+ \* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2
- interventionNames
- Procedure: Multidisciplinary cooperative comprehensive treatment
- label
- Triple negative
- description
- ER- PR-,HER2- \* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2
- interventionNames
- Procedure: Multidisciplinary cooperative comprehensive treatment
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: 1. Pathological and immunohistochemical diagnosis of breast cancer by biopsy 2. No MRI contraindications and no biopsy before MRI 3. Without radiotherapy and chemotherapy before enrollment Exclusion Criteria: 1. Those with previous history of breast cancer surgery, hormone replacement therapy and chest radiotherapy 2. Patients with severe diseases who cannot cooperate with the examination 3. People with contraindications to MRI 4. The researchers believe that other conditions are not suitable for breast MRI examination
References
Publications (0)
Data not yet available